Aligos Therapeutics Inc (ALGS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aligos Therapeutics Inc (ALGS) has a cash flow conversion efficiency ratio of -0.728x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-23.13 Million) by net assets ($31.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ALGS net asset quality score to measure how much of total assets are equity-financed.
Aligos Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Aligos Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Aligos Therapeutics Inc (ALGS) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Aligos Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aligos Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Inventec Besta Co Ltd
TW:8201
|
-0.006x |
|
Local Bounti Corp
NYSE:LOCL
|
0.034x |
|
Hamelin Gold Ltd
AU:HMG
|
-0.017x |
|
Daebo Magnetic Co.Ltd
KQ:290670
|
-0.063x |
|
Compugates Holdings Bhd
KLSE:5037
|
0.040x |
|
Sungwoo Electronics Co. Ltd
KQ:081580
|
0.042x |
|
Barinthus Biotherapeutics plc
NASDAQ:BRNS
|
-0.127x |
|
aXichem AB
ST:AXIC-A
|
-0.034x |
Annual Cash Flow Conversion Efficiency for Aligos Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Aligos Therapeutics Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see ALGS market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $53.55 Million | $-82.50 Million | -1.541x | -155.29% |
| 2024-12-31 | $-28.97 Million | $-80.74 Million | 2.787x | +424.84% |
| 2023-12-31 | $92.08 Million | $-79.00 Million | -0.858x | -12.28% |
| 2022-12-31 | $103.90 Million | $-79.39 Million | -0.764x | -22.04% |
| 2021-12-31 | $184.73 Million | $-115.66 Million | -0.626x | -85.51% |
| 2020-12-31 | $220.04 Million | $-74.26 Million | -0.337x | -146.83% |
| 2019-12-31 | $-64.89 Million | $-46.77 Million | 0.721x | +63.80% |
| 2018-12-31 | $-13.75 Million | $-6.05 Million | 0.440x | -- |
About Aligos Therapeutics Inc
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifosc… Read more